MicroRNAs (miRNAs) are small noncoding regulatory RNAs that are often dysregulated during carcinogenesis. Downregulation of let-7 miRNA in many human cancers indicates its role in tumourigenesis. This study evaluated the levels of let-7c miRNA, using real-time reverse transcription−polymerase chain reaction, between 32 hepatocellular carcinoma (HCC) tissues and matched normal adjacent tumour tissues within the context of the patient's clinical pathology. Levels of let-7c miRNA were significantly lower in HCC tissues than in corresponding normal adjacent tumour tissues and there was a correlation between the downregulation of let-7c and poor tissue differentiation in HCC. There was no correlation between let-7c miRNA levels and other clinicopathological factors, such as patient age, sex, hepatitis B virus status, a-fetoprotein levels, tumour size, tumour number, the presence of cirrhosis, liver envelope invasion or portal vein thrombosis. These data suggested that let-7c microRNA may play a role in regulating HCC cell differentiation.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality, resulting in 598 000 deaths per year worldwide. 1 About 626 000 cases are diagnosed each year. 2 The distribution of HCC favours developing countries (82% of cases worldwide), with 55% of cases in China alone. 1 Analysing and identifying the molecular characteristics of HCC may improve the management of this malignancy.
MicroRNAs (miRNAs) are small nonprotein-coding RNAs, approximately 22 nucleotides in length, that regulate gene expression post-transcription by inhibiting translation or promoting degradation of target mRNAs. 3 Computational analyses predict that miRNAs may regulate approximately 30% of all human genes and that each miRNA can individually regulate hundreds of targets. 4 Although the precise biological functions of miRNAs are not yet fully understood, they are known to have diverse expression patterns and regulate various developmental and physiological processes. 5 Moreover, differential expression of miRNA may contribute to a variety of human diseases, including cancer. 5 In humans, 12 genomic loci encode the let-7 family members (let-7a-1, -2, -3, let-7b, let-7c, let-7d, let-7e, let-7f-1, -2, let-7g, let-7i, miR98).
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The let-7 miRNAs are widely viewed as tumour suppressors, as many human let-7 genes map to regions that are altered or deleted in human tumours. For example, let-7 family members appear to be downregulated in lung cancer, 6,7 breast cancer, 8 acute lymphoblastic leukaemia, 9 pancreatic cancer 10 and hepatocellular carcinoma. 11 The present study examined the level of let-7c miRNA in 32 cases of HCC and evaluated the relationship between let-7c miRNA levels and various clinicopathological factors in order to establish a better understanding of the possible role of let-7c in HCC.
Patients and methods

STUDY POPULATION
In this retrospective study, freshly isolated human HCC tissues and paired normal adjacent tissues (> 3 cm from the cancer tissue) were obtained from patients who had undergone surgery at the Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, between August 2008 and August 2009. All patients included in the study had to have been newly diagnosed with HCC and have not received any radiotherapy, chemotherapy or immunotherapy prior to surgery. The diagnosis and histological grade of each case was confirmed by two pathologists using the American Joint Committee on Cancer (AJCC) classification. 12 All patients provided verbal informed consent to be included in the study and the study was approved by the Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine.
EXTRACTION AND ANALYSIS OF
LET-7 MIRNA
Levels of let-7 miRNA were analysed by real-time reverse transcription-polymerase chain reaction (RT-PCR). All tissue samples were stored in liquid nitrogen until analysis. Total RNA was extracted from 100 mg tissue using TRIzol ® reagent (Invitrogen Corp., Carlsbad, CA, USA) and small RNA isolation and enrichment were performed using the mirVana™ miRNA Isolation Kit (Applied Biosystems/Ambion Inc., Austin, TX, USA) according to the manufacturer's instructions. The RNA concentration and purity were assessed by UV spectrophotometry (A 260 /A 280 ratio of 1.8 − 2.0). Total RNA samples were reverse transcribed to cDNA using a TaqMan ® microRNA assay miRNA-specific stem-loop primer and the TaqMan ® microRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The PCR was performed using the TaqMan ® Universal PCR Master Mix and a 7500 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions, and previously published primer sequences. 13 The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 60 s and elongation at 60°C for 60 s. The U6 small nuclear (sn)RNA was amplified as an internal control using previously published primer sequences. 14 
Each sample was analysed in triplicate.
Levels of let-7c miRNA were analysed quantitatively relative to U6 snRNA by the 2 -∆∆CT method 15 using the equation, relative quantity = 2 -∆∆CT , where ∆∆CT = (CT let-7c -CT U6 ) cancer -(CT let-7c -CT U6 ) normal adjacent tissues , and CT is the cycle threshold.
STATISTICAL ANALYSES
All statistical analyses were performed with the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All data were expressed as mean ± SD. Levels Let-7c microRNA in hepatocellular carcinoma of let-7c miRNA in HCC and normal adjacent tissues were compared using Student's t-test, and the correlation between let-7c miRNA levels and various clinicopathological factors was analysed using a two-sided Fisher's exact test. A value of P < 0.05 was considered to be statistically significant.
Results
In total, 32 patients (20 males, 12 females) were included in the study and HCC and corresponding normal adjacent tissues from each patient were analysed. The mean ± SD age of the patients was 50.6 ± 10.4 years and their mean ± SD disease duration was 6.4 ± 2.6 months. According to the tumour, node, metastasis classification of the AJCC, 12 there were six patients with stage I, eight with stage II, 11 with stage III and seven with stage IV HCC.
The let-7c miRNA was detected in all 32 HCC tissues; the relative levels of let-7c miRNA in the tumour samples and the normal adjacent tissues for each of the 32 patients are shown in Fig. 1A . In the majority of patients (28/32, 87.5%), let-7c was downregulated in HCC tissues compared with normal adjacent tissues, with a mean ± SD fold decrease to 0.58 ± 0.52 (P < 0.001, t = -4.569; Fig. 1B) . The let-7c miRNA levels in 18 out of 32 tumour tissue samples (56.25%) were reduced by ≥ 50% compared with levels in normal adjacent tissues. The patients were divided into two groups:
those with low let-7c miRNA (reduced by ≥ 50% relative to normal adjacent tissues, n = 18) and those with high let-7c miRNA (reduced by < 50% or increased relative to normal adjacent tissues, n = 14). The relationship between let-7c miRNA level and the clinicopathological characteristics of the HCC patients are summarized in Table 1 .
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Discussion
There has been increasing evidence demonstrating a strong link between miRNAs and human cancer, and changes in miRNA have been observed in a variety of human tumours, 16 including chronic lymphocytic leukaemia, 17 lung adenocarcinoma, 18 breast carcinoma, 19 endocrine pancreatic tumours, 20 hepatocellular carcinoma, 21 papillary thyroid carcinoma, 22 and colorectal cancer. 23 In addition, human miRNA genes are frequently located at fragile sites and other cancer-associated chromosomal regions that are commonly genetically altered in human cancers. 24 Linking miRNAs to human cancer is further supported by the fact that miRNAs have been shown to act either as oncogenes or tumour suppressors. 3 The present study demonstrated that let-7c miRNA was significantly downregulated in HCC tissues compared with normal adjacent tissues from the same patients. Consistent with this, let-7 family members are downregulated in many other cancer types. For example, let-7g, which maps to 3p21, has been implicated in the initiation of lung cancers. 24 Overexpression of let-7 inhibits lung cancer cell growth, whereas inhibition of let-7 function in A549 lung cancer cells has been shown to promote proliferation, 6, 7, 25 indicating that let-7 functions as a tumour suppressor. 18 In lung adenocarcinoma and squamous cell carcinoma, let-7 has also been shown to be present at lower levels than in normal lung tissue and the loss or reduction of let-7 family members, specifically let-7a-2, correlates with poor survival in lung cancer. 6, 7, 26 Let-7d levels are reduced in head and neck squamous cell carcinoma and are predictive of poor survival. 25 Taken together, these studies suggest that let-7 is downregulated in various cancers and is a candidate tumour suppressor and prognostic marker.
The role of let-7 in the differentiation of many cell types across multiple organisms during embryonic development has been firmly established. It is a marker of fully differentiated cells and it is undetectable in stem cells. 27 Furthermore, there is a very clear correlation between reduction in let-7 levels and the development of poorly differentiated, aggressive cancers. 28 In agreement with other reports, 6,7,25 a reduction in let-7c miRNA levels was observed in the present study and this was associated with poor tissue differentiation, but not with other clinicopathological parameters. Ricarte-Filho et al. 29 reported that the effects of let-7f on thyroid growth and differentiation might attenuate the neoplastic process of RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase in papillary thyroid oncogenesis through impairment of the mitogen-activated protein kinase signalling pathway. Another study showed that let-7b regulates neural stem cell differentiation by targeting nuclear receptor subfamily 2 group E member 1 signalling. 30 These data indicate that let-7 can regulate cell differentiation, which may explain the association between the downregulation of let-7c and poor tissue differentiation in HCC. date, the precise molecular mechanisms behind the altered expression of let-7 family members in tumours are unclear. The tumour suppressor and antiproliferative effects of let-7 are exerted by repressing several oncogenes and influencing key regulators of the cell cycle, cell differentiation and apoptotic pathways. In more differentiated tumour cells, let-7 is present at higher levels and its target oncogenes, high mobility group A2 (HMGA2) and Ras, are downregulated. Thus, loss of let-7 can act as a marker for less differentiated cancer. 31 Ras oncogenes, which are frequently deregulated in many human cancers, and HMGA2, which is upregulated in various benign and malignant tumours, are targets of let-7 and are upregulated both in liver and lung cancer cells. 32 Additionally, let-7g can target type I collagen α2 and inhibit cell migration in HCC. 33 The present study demonstrated a role for let-7c in the development and progression of HCC and let-7c may, therefore, be promising as a diagnostic marker and therapeutic target for HCC. By further identifying the targets of let-7c, future novel therapeutic strategies based on let-7c activity may be useful in patients with HCC.
In summary, the present study demonstrated that let-7c miRNA is downregulated in HCC and that this is associated with poor tissue differentiation in these tumours, indicating that let-7c may play a role in the differentiation process of HCC. The precise molecular mechanism of let-7c in HCC needs further investigation.
